GNFT Genfit S.A.

11.56USD10.54 EUR · EPA+1.54%Mkt Cap: 579.18M USDP/E: —

Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally. The company offers elafibranor for the treatment of primary biliar…

Institutional holders6 on file

Key Statistics

Company
Market Cap579.18M USD
Enterprise Value650.17M USD
Revenue (TTM)65.25M USD
Gross Profit71.44M USD
Net Income (TTM)-94.29M USD
Revenue/Share1.31 USD
Last Price11.56 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees180
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004163111
Valuation
P/E (Trailing)—
P/E (Forward)14.64
PEG—
EV/EBITDA-9.80
EV/Revenue9.96
P/S8.88
P/B-10.87
EPS (TTM)-2.24 USD
EPS (Forward)0.79 USD
52W Range
4.06358% of range16.98
52W High16.98 USD
52W Low4.063 USD
Profitability
Gross Margin99.54%
Oper. Margin-104.81%
EBITDA Margin-101.68%
Profit Margin-131.38%
ROE381.47%
ROA-54.05%
ROIC-196.74%
ROCE-61.76%
Growth
Revenue Growth-32.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.78M USD
CapEx (TTM)3.75M USD
FCF Margin-37.55%
FCF Yield-4.23%
Net Debt71.79M USD
Net Debt/EBITDA-1.08
Net Debt/FCF—
Balance Sheet
Debt/Equity-6.69
Current Ratio1.58
Quick Ratio1.55
Book Value/Sh-1.06 USD
Cash/Share2.50 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)23.73 USD
Upside (mean)+105.3%
Target Range16.45 USD – 27.64 USD
16.45+105.3% to mean27.64
# Analysts5
Ownership
Shares Out.50.10M
Float41.07M
Insiders13.22%
Institutions14.30%
Technical
SMA 5011.09 (+4.2%)
SMA 20011.31 (+2.2%)
Beta1.20
S&P 52W Chg12.00%
Avg Vol (30d)295.01K
Avg Vol (10d)235.49K
Technical Indicators
RSI (14)51.6
MACD0.1544
MACD Signal0.1978
MACD Hist.-0.0434
BB Upper13.26 USD
BB Middle11.64 USD
BB Lower10.01 USD
BB Width27.88%
ATR (14)0.7059 USD
Vol Ratio (20d)0.69x

About Genfit (EPA: GNFT)

›

Genfit (EPA: GNFT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 180 employees.

The shares were at 10.54 EUR on 19 November 2026, up 182.3% over 52 weeks. Its 52-week range is 3.704 EUR to 15.48 EUR: the price is 31.9% below the high and 184.6% above the low.

Its market capitalisation is 528.07M EUR.

Genfit reports return on equity of 381.5%, an operating margin of -104.8% and revenue down 32.0% year over year.

Its debt exceeds its cash by 65.46M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 21.64 EUR is 105.3% above the current price. The next earnings report is expected on 5 April 2027.